In a report issued on May 5, Mani Foroohar from SVB Securities reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), with a price target of $64.00. The company's shares closed last Friday at $9.45, close to its 52-week low of $9.29. According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.2% and a 31.9% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Arrowhead Pharmaceuticals, and Recursion Pharmaceuticals. Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $58.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-rocket-pharmaceuticals-rckt?utm_source=advfn.com&utm_medium=referral